American Journal of Clinical Nutrition, Vol 68, 1180-1186, Copyright © 1998 by The American Society for Clinical Nutrition, Inc

ORIGINAL RESEARCH COMMUNICATIONS

Thermogenic effects of sibutramine in humans

DL Hansen, S Toubro, MJ Stock, IA Macdonald and A Astrup
Research Department of Human Nutrition, The Royal Veterinary and Agricultural University, Frederiksberg, Denmark. dlh@kvl.dk

BACKGROUND: Sibutramine is an effective compound for the treatment of obesity, acting both on serotonergic and noradrenergic pathways. Animal studies have shown that sibutramine exerts its effect by enhancing satiety as well as by increasing thermogenesis. OBJECTIVE: We tried to compare the acute thermogenic effect of a single 30-mg dose of sibutramine with placebo on basal energy expenditure (EE) and diet- induced thermogenesis. DESIGN: The study was randomized, double-blind, and placebo controlled. Eleven healthy, normal-weight men underwent 4 distinct treatment regimens separated by washout periods of 6-10 d. EE was measured by indirect calorimetry before and for 5.5 h after sibutramine or placebo administration with or without a 2.1-MJ breakfast. Visual analogue scales for assessment of appetite were completed hourly. RESULTS: Sibutramine caused a significant increase in EE above that for placebo (over 5.5 h) during both the fed (34%, 0.15 kJ/min) and fasted (183%, 0.20 kJ/min) states (P < 0.02) as well as during the last 3.5 h of this 5.5-h period and in the fed (87%, 0.26 kJ/min) and fasted (152%, 0.22 kJ/min) states, respectively (P < 0.01). The sibutramine-induced increase in EE was accompanied by an increase in plasma epinephrine (P < 0.01), heart rate (P < 0.001), blood pressure (P < 0.05), and plasma glucose (P < 0.02). About 25% of the increased heart rate with sibutramine could be explained by increased thermogenesis. Sibutramine increased satiety more than did placebo (5-h area under the curve, P < 0.05). CONCLUSIONS: Sibutramine caused a significant increase in both EE and satiety, which may both contribute to its weight-reducing properties.

This article has been cited by other articles:

				J. Wilding and N. Finer Weight management and cardiovascular disease: implications of recent and ongoing clinical trials The British Journal of Diabetes & Vascular Disease, July 1, 2008; 8(4): 170 - 176. [Abstract] [PDF]

				M. M. Huizinga Weight-Loss Pharmacotherapy: A Brief Review Clin. Diabetes, October 1, 2007; 25(4): 135 - 140. [Abstract] [Full Text] [PDF]

				G. A. Bray and F. L. Greenway Pharmacological Treatment of the Overweight Patient Pharmacol. Rev., June 1, 2007; 59(2): 151 - 184. [Full Text] [PDF]

				E. G. A. H. Van Mil, K. R. Westerterp, A. D. M. Kester, H. A. Delemarre-van de Waal, W. J. M. Gerver, and W. H. M. Saris The Effect of Sibutramine on Energy Expenditure and Body Composition in Obese Adolescents J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1409 - 1414. [Abstract] [Full Text] [PDF]

				N. Finer Does pharmacologically induced weight loss improve cardiovascular outcome? Impact of anti-obesity agents on cardiovascular risk factors Eur. Heart J. Suppl., November 1, 2005; 7(suppl_L): L32 - L38. [Abstract] [Full Text] [PDF]

				A. M. Sharma Does pharmacologically induced weight loss improve cardiovascular outcome? Sibutramine pharmacology and the cardiovascular system Eur. Heart J. Suppl., November 1, 2005; 7(suppl_L): L39 - L43. [Abstract] [Full Text] [PDF]

				B. CANNON and J. NEDERGAARD Brown Adipose Tissue: Function and Physiological Significance Physiol Rev, January 1, 2004; 84(1): 277 - 359. [Abstract] [Full Text] [PDF]

				M Labib The investigation and management of obesity J. Clin. Pathol., January 1, 2003; 56(1): 17 - 25. [Abstract] [Full Text] [PDF]

				C. Day and C. J Bailey Sibutramine update The British Journal of Diabetes & Vascular Disease, September 1, 2002; 2(5): 392 - 397. [Abstract] [PDF]

				S. R. Smith, L. de Jonge, M. Pellymounter, T. Nguyen, R. Harris, D. York, S. Redmann, J. Rood, and G. A. Bray Peripheral Administration of Human Corticotropin-Releasing Hormone: A Novel Method to Increase Energy Expenditure and Fat Oxidation in Man J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 1991 - 1998. [Abstract] [Full Text]

				I. W Campbell The STORM report: implications for care: The appropriate use of sibutramine in Primary care is discussed by Dr Ian Campbell, Chair of the National Obesity Forum The British Journal of Diabetes & Vascular Disease, March 1, 2001; 1(2): 118 - 121. [Abstract] [PDF]

				B. E. Levin and A. A. Dunn-Meynell Sibutramine alters the central mechanisms regulating the defended body weight in diet-induced obese rats Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2000; 279(6): R2222 - R2228. [Abstract] [Full Text] [PDF]

				G. A. Bray and F. L. Greenway Current and Potential Drugs for Treatment of Obesity Endocr. Rev., December 1, 1999; 20(6): 805 - 875. [Abstract] [Full Text]